GlaxoSmithKline PLC (NYSE:GSK) shares gapped up prior to trading on Tuesday . The stock had previously closed at $43.04, but opened at $43.17. GlaxoSmithKline PLC shares last traded at $43.49, with a volume of 2,739,566 shares traded.

Several brokerages recently issued reports on GSK. Citigroup Inc. upgraded shares of GlaxoSmithKline PLC from a “neutral” rating to a “buy” rating in a research report on Wednesday, March 30th. Beaufort Securities reiterated a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Friday, April 1st. Cowen and Company lowered shares of GlaxoSmithKline PLC from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 26th. Zacks Investment Research lowered shares of GlaxoSmithKline PLC from a “hold” rating to a “sell” rating in a research report on Wednesday, April 6th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Monday, April 25th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $46.86.

The stock’s 50 day moving average is $42.01 and its 200-day moving average is $41.05. The firm has a market capitalization of $105.38 billion and a price-to-earnings ratio of 127.600.

The business also recently disclosed a dividend, which will be paid on Thursday, July 14th. Shareholders of record on Friday, May 13th will be given a dividend of $0.549 per share. The ex-dividend date is Wednesday, May 11th.

Several large investors have modified their holdings of GSK. ProVise Management Group LLC acquired a new stake in shares of GlaxoSmithKline PLC during the fourth quarter worth approximately $1,008,000. Rhumbline Advisers boosted its stake in shares of GlaxoSmithKline PLC by 5.1% in the fourth quarter. Rhumbline Advisers now owns 26,550 shares of the pharmaceutical company’s stock worth $1,071,000 after buying an additional 1,300 shares during the period. Camelot Portfolios LLC boosted its stake in shares of GlaxoSmithKline PLC by 24.1% in the fourth quarter. Camelot Portfolios LLC now owns 28,979 shares of the pharmaceutical company’s stock worth $1,169,000 after buying an additional 5,626 shares during the period. Profund Advisors LLC boosted its stake in shares of GlaxoSmithKline PLC by 16.7% in the fourth quarter. Profund Advisors LLC now owns 30,310 shares of the pharmaceutical company’s stock worth $1,223,000 after buying an additional 4,340 shares during the period. Finally, Hamilton Point Investment Advisors LLC boosted its stake in shares of GlaxoSmithKline PLC by 11.0% in the fourth quarter. Hamilton Point Investment Advisors LLC now owns 33,846 shares of the pharmaceutical company’s stock worth $1,366,000 after buying an additional 3,350 shares during the period.

GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.